According to the Zhongtong Finance and Economics APP report, Uni Medical (02666) announced that in the first three quarters of 2024, the group promoted the high-quality development of medical and health business, overall operating performance was stable and improving, key works achieved positive results. As of the nine months ended September 30, 2024, the group's revenue decreased slightly by about 1.2% compared to the same period last year, and the net profit attributable to ordinary equity holders increased by about 5.1% compared to the same period last year.

Furthermore, based on the Hang Seng Index Limited's quarterly adjustment results of the Hang Seng Series Indices announced on August 16, 2024, and officially implemented on September 9, the group's industry classification has been changed from 'Financials' to 'Medical Care' and officially entered the Hang Seng Healthcare Index. This adjustment of industry classification is due to the significant growth in the group's performance in the medical and health field in recent years, also representing the recognition by Hang Seng Index Limited of Uni Medical's development potential in the medical and health sector, which will further increase the attention of Uni Medical in the capital markets, effectively support the listed companies in market cap management related work, and enhance the development quality of central enterprise-controlled listed companies.

In terms of comprehensive medical business, the group continues to focus on the four support objectives of 'comfortable environment, first-class service, excellent technology, and efficient operation' to empower the development of state-owned hospitals, improve operational efficiency and benefits. The overall operational situation of the group's affiliated medical institutions in the first three quarters of 2024 was good: the number of outpatient visits increased by about 4.9% compared to the same period last year, and the total number of discharged patients increased by about 6.7% compared to the same period last year. The average length of hospital stay decreased to 9.8 days, the bed occupancy rate remained at a high level of around 90%, and operational efficiency continued to improve.

In terms of specialized and health technology, the group focuses on core medical resources, adheres to the 'dual-drive' development of connotation and extension, while improving quality and efficiency internally, gradually building a large health ecological system, providing technological engine for innovative development, and creating new profit growth points for the company. Currently, various aspects of this sector are making new progress in layout expansion and capacity building, further solidifying the industrialization foundation. As of the nine months ended September 30, 2024, the revenue from full-cycle management of medical devices was 0.4233 billion yuan, an increase of about 515.1% year-on-year, and the net profit was 49.6 million yuan, an increase of about 263.8% year-on-year. In September, the company has completed the acquisition and delivery of Shandong University of Traditional Chinese Medicine Affiliated Eye Hospital and Shandong Qingniao Soft Comm. Ltd. (a company listed on the National Equities Exchange and Quotations with the stock code 831718). In addition, other specialized medical institutions and health technology companies' merger projects are progressing smoothly.

In terms of financial business, the group adheres to the functional positioning of serving the real economy and the main business development, promotes the integration of production and finance, and guarantees the safe and stable development of the business. On the cost side, the group closely follows market changes, actively uses various domestic and foreign financing tools while ensuring reasonable and adequate liquidity and sound liability maturity structure, effectively controls the overall financing cost. As of September 30, 2024, the total interest-earning assets of the group continued to grow after the mid-year of 2024, with steady improvement in net interest margin and net profit margin, and the asset quality remains good with the provision coverage maintained prudently.